Alpha 2.0
Login Register
» Authors » Thomas Emm

Thomas Emm

Explore the profile of Thomas Emm including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 273
Followers 0
Related Specialties
Pharmacology
Chemistry
Biology
Top 10 Co-Authors
Swamy Yeleswaram
Peggy A Scherle
William V Williams
Yvonne Lo
Jack G Shi
Xuejun Chen
Robert R Landman
Ryan F McGee
Naresh G Punwani
Naresh Punwani
Published In
J Clin Pharmacol
J Med Chem
Biomed Chromatogr
Drug Metab Dispos
Clin Pharmacol Drug Dev
Affiliations
Soon will be listed here.
Recent Articles
1.
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients
Chen X, Shi J, Emm T, Scherle P, McGee R, Lo Y, et al.
Clin Pharmacol Drug Dev . 2016 Apr; 3(1):34-42. PMID: 27128228
Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single-dose studies. Ruxolitinib area under the curve...
2.
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
Shi J, Chen X, Lee F, Emm T, Scherle P, Lo Y, et al.
J Clin Pharmacol . 2014 Jun; 54(12):1354-61. PMID: 24965573
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in...
3.
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers
Shi J, Chen X, Emm T, Scherle P, McGee R, Lo Y, et al.
J Clin Pharmacol . 2011 May; 52(6):809-18. PMID: 21602517
Ruxolitinib, a selective Janus kinase (JAK) 1&2 inhibitor in development for the treatment of myeloproliferative neoplasms, is primarily metabolized by CYP3A4. The effects of inhibition or induction of CYP3A4 on...
4.
Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS/MS using supported liquid extraction
Li Y, Emm T, Yeleswaram S
Biomed Chromatogr . 2011 Feb; 25(11):1245-51. PMID: 21308704
A rapid, sensitive and selective bioanalytical method was developed for the simultaneous determination of fluoxetine and its primary metabolite norfluoxetine in human plasma. Sample preparation was based on supported liquid...
5.
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers
Shi J, Chen X, McGee R, Landman R, Emm T, Lo Y, et al.
J Clin Pharmacol . 2011 Jan; 51(12):1644-54. PMID: 21257798
INCB018424 phosphate, a potent inhibitor of JAK enzymes with selectivity for JAK1&2, is in development for the treatment of myelofibrosis (MF). The oral dose pharmacokinetics, pharmacodynamics, safety, and tolerability of...
6.
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans
Shilling A, Nedza F, Emm T, Diamond S, McKeever E, Punwani N, et al.
Drug Metab Dispos . 2010 Aug; 38(11):2023-31. PMID: 20699411
The metabolism, excretion, and pharmacokinetics of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (INCB018424), a potent, selective inhibitor of Janus tyrosine kinase1/2 and the first investigational drug of its class in phase III studies for the...
7.
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic
Combs A, Zhu W, Crawley M, Glass B, Polam P, Sparks R, et al.
J Med Chem . 2006 Jun; 49(13):3774-89. PMID: 16789735
Potent nonpeptidic benzimidazole sulfonamide inhibitors of protein tyrosine phosphatase 1B (PTP1B) were derived from the optimization of a tripeptide containing the novel (S)-isothiazolidinone ((S)-IZD) phosphotyrosine (pTyr) mimetic. An X-ray cocrystal...